Treatment-Free Remission Feasible After Nilotinib in CML

Share this content:
Treatment-Free Remission Feasible After Nilotinib in CML
Treatment-Free Remission Feasible After Nilotinib in CML

MONDAY, Feb. 26, 2018 (HealthDay News) -- For patients with chronic-phase chronic myeloid leukemia (CML), treatment-free remission (TFR) appears to be feasible after second-line nilotinib, according to a study published online Feb. 20 in the Annals of Internal Medicine.

François-Xavier Mahon, M.D., Ph.D., from the University of Bordeaux in France, and colleagues conducted an open-label study to assess TFR after discontinuation of second-line nilotinib. Adults with CML in chronic phase who received tyrosine kinase inhibitor (TKI) treatment for at least three years and achieved molecular response (MR)4.5 (BCR-ABL1 ≤0.0032 percent on the International Scale) while receiving nilotinib entered a one-year consolidation phase. Those with sustained MR4.5 during consolidation were able to enter TFR (discontinuation of TKI therapy).

A total of 163 patients who had switched from imatinib to nilotinib were enrolled in the study and entered the consolidation phase; 126 of these patients met the criteria for entering the TFR phase. The researchers found that 58 and 53 percent of patients, respectively, maintained TFR at 48 and 96 weeks. Fifty-six patients reinitiated nilotinib therapy; 55 and 52 regained major MR or better and MR4.5, respectively. CML did not progress to accelerated phase or blast crisis in any of the patients. During the first 48 weeks after nilotinib discontinuation, musculoskeletal pain was more frequent.

"TFR seems achievable in patients with sustained MR4.5 after switching to nilotinib," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Novartis, which manufactures nilotinib and provided funding for the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Patient-Reported Outcome Measures May Aid Communication

Patient-Reported Outcome Measures May Aid Communication

Usefulness of PROs varies based on how much doctors value, prioritize, and use them

Negative Attitudes Reported Toward Weight-Loss Surgery

Negative Attitudes Reported Toward Weight-Loss Surgery

Women more likely to think surgery is needed for health, less likely to consider it 'easy way out'

Risk for Hospitalization for Heart Failure Greater With Diabetes

Risk for Hospitalization for Heart Failure Greater With ...

Rate has declined but remains higher in those with type 1 or 2 diabetes than in those without

is free, fast, and customized just for you!




Already a member?

Sign In Now »